
Spruce Biosciences, Inc.
Spruce Biosciences, Inc. (SPRB) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · SPRB · as of Jun 9, 2026
Activity summary
Buy transactions
1
P-Purchase only
Sell transactions
2
12 Months
Buy/Sell ratio
0.50
Buy/Sell (by trades)
Overall sentiment
Spruce Biosciences, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
SPRB insider buying and selling by quarter
SPRB insider selling · SPRB insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · SPRB ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
SPRB executive sell shares · SPRB board member insider trading · SPRB insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Dec 11, 2025 | Ways Douglas Kirk Interim Chief Medical Officer · Director | Option | 1,250 | — | Form 4 |
| Dec 31, 2025 | Szwarcberg Javier B. CHIEF EXECUTIVE OFFICER · Director | Award | 4,690 | $21K | Form 4 |
| Dec 15, 2025 | Gharib Samir M. PRESIDENT AND CFO | Option | 513 | — | Form 4 |
| Dec 15, 2025 | Gharib Samir M. PRESIDENT AND CFO | Other | 184 | $15K | Form 4 |
| Dec 15, 2025 | Gharib Samir M. PRESIDENT AND CFO | Option | 496 | — | Form 4 |
| Dec 15, 2025 | Gharib Samir M. PRESIDENT AND CFO | Other | 178 | $14K | Form 4 |
| Dec 15, 2025 | Szwarcberg Javier B. CHIEF EXECUTIVE OFFICER · Director | Option | 1,196 | — | Form 4 |
| Dec 15, 2025 | Szwarcberg Javier B. CHIEF EXECUTIVE OFFICER · Director | Option | 1,480 | — | Form 4 |
| Dec 15, 2025 | Szwarcberg Javier B. CHIEF EXECUTIVE OFFICER · Director | Other | 608 | $49K | Form 4 |
| Dec 15, 2025 | Szwarcberg Javier B. CHIEF EXECUTIVE OFFICER · Director | Other | 752 | $61K | Form 4 |
| Dec 11, 2025 | Gharib Samir M. PRESIDENT AND CFO | Option | 1,900 | — | Form 4 |
| Dec 11, 2025 | Gharib Samir M. PRESIDENT AND CFO | Other | 680 | $60K | Form 4 |
| Dec 10, 2025 | Gharib Samir M. PRESIDENT AND CFO | Option | 514 | — | Form 4 |
| Dec 10, 2025 | Gharib Samir M. PRESIDENT AND CFO | Other | 184 | $16K | Form 4 |
| Dec 11, 2025 | Szwarcberg Javier B. CHIEF EXECUTIVE OFFICER · Director | Option | 4,950 | — | Form 4 |
| Dec 11, 2025 | Szwarcberg Javier B. CHIEF EXECUTIVE OFFICER · Director | Other | 2,194 | $194K | Form 4 |
| Dec 10, 2025 | Szwarcberg Javier B. CHIEF EXECUTIVE OFFICER · Director | Option | 1,196 | — | Form 4 |
| Dec 10, 2025 | Szwarcberg Javier B. CHIEF EXECUTIVE OFFICER · Director | Other | 428 | $37K | Form 4 |
| Oct 20, 2025 | Gharib Samir M. PRESIDENT AND CFO | Option | 2,053 | — | Form 4 |
| Oct 20, 2025 | Gharib Samir M. PRESIDENT AND CFO | Other | 661 | $98K | Form 4 |
| Oct 20, 2025 | Szwarcberg Javier B. CHIEF EXECUTIVE OFFICER · Director | Option | 4,784 | — | Form 4 |
| Oct 20, 2025 | Szwarcberg Javier B. CHIEF EXECUTIVE OFFICER · Director | Other | 1,539 | $228K | Form 4 |
Ways Douglas Kirk
Interim Chief Medical Officer · Director
Date
Dec 11
Shares
1,250
Price
—
Value
—
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER · Director
Date
Dec 31
Shares
4,690
Price
$4.53
Value
$21K
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER · Director
Date
Dec 15
Shares
1,196
Price
—
Value
—
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER · Director
Date
Dec 15
Shares
1,480
Price
—
Value
—
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER · Director
Date
Dec 15
Shares
608
Price
$80.67
Value
$49K
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER · Director
Date
Dec 15
Shares
752
Price
$80.67
Value
$61K
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER · Director
Date
Dec 11
Shares
4,950
Price
—
Value
—
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER · Director
Date
Dec 11
Shares
2,194
Price
$88.41
Value
$194K
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER · Director
Date
Dec 10
Shares
1,196
Price
—
Value
—
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER · Director
Date
Dec 10
Shares
428
Price
$85.67
Value
$37K
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER · Director
Date
Oct 20
Shares
4,784
Price
—
Value
—
Szwarcberg Javier B.
CHIEF EXECUTIVE OFFICER · Director
Date
Oct 20
Shares
1,539
Price
$148.16
Value
$228K
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About SPRB insider trading
SPRB insider trades
Spruce Biosciences, Inc. (SPRB) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Szwarcberg Javier B. (CHIEF EXECUTIVE OFFICER · Director), Gharib Samir M. (PRESIDENT AND CFO), Ways Douglas Kirk (Interim Chief Medical Officer · Director). Over the past 12 months, 3 insiders have filed transactions with the SEC. SPRB insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Spruce Biosciences, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
SPRB insider trading · 5 questionsThe insiders of Spruce Biosciences, Inc. (SPRB) include executives and directors such as Szwarcberg Javier B. (CHIEF EXECUTIVE OFFICER · Director), Gharib Samir M. (PRESIDENT AND CFO), Ways Douglas Kirk (Interim Chief Medical Officer · Director), among others. Over the past 12 months, 3 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026